Drusano G L, Joshi J, Forrest A, Ruxer R, Standiford H, Leslie J, Wade J, Schimpff S
Antimicrob Agents Chemother. 1985 Apr;27(4):605-7. doi: 10.1128/AAC.27.4.605.
We administered 2 g of ceftazidime intravenously every 8 h to cancer patients for the empiric therapy of febrile episodes. Ceftazidime was administered as monotherapy for patients with granulocyte counts in excess of 1,000/microliter. Febrile, neutropenic patients were randomized to also receive either piperacillin or tobramycin. The pharmacokinetic profile of ceftazidime during a steady-state dosing interval was ascertained in 21 patients. No differences were seen between groups for any of the pharmacokinetic parameters examined. As expected, the observed half-life was longer, the serum clearance was smaller, and the volumes of distribution were larger than in previously reported studies of volunteers. Serum concentrations remained above the MIC for inhibition of 90% of strains of the most common bacteremic pathogens seen in our cancer center for the entire 8-h dosing interval.
我们每8小时给癌症患者静脉注射2克头孢他啶，用于发热性发作的经验性治疗。对于粒细胞计数超过1000/微升的患者，头孢他啶作为单一疗法给药。发热性中性粒细胞减少患者被随机分组，分别接受哌拉西林或妥布霉素治疗。在21名患者中确定了头孢他啶在稳态给药间隔期间的药代动力学特征。在所检查的任何药代动力学参数方面，各组之间均未观察到差异。正如预期的那样，观察到的半衰期更长，血清清除率更小，分布容积比先前报道的志愿者研究中的更大。在整个8小时给药间隔内，血清浓度保持在抑制我们癌症中心所见最常见菌血症病原体90%菌株的最低抑菌浓度以上。
